0000899243-19-017825.txt : 20190621
0000899243-19-017825.hdr.sgml : 20190621
20190621172030
ACCESSION NUMBER: 0000899243-19-017825
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190619
FILED AS OF DATE: 20190621
DATE AS OF CHANGE: 20190621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Buell Jennifer
CENTRAL INDEX KEY: 0001711184
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 19912439
BUSINESS ADDRESS:
BUSINESS PHONE: 781-674-4400
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-19
0
0001098972
AGENUS INC
AGEN
0001711184
Buell Jennifer
C/O AGENUS INC.
3 FORBES ROAD
LEXINGTON
MA
02421
0
1
0
0
Chief Operating Officer
Stock Option (right to buy)
2.38
2019-06-19
4
A
0
300000
0.00
A
2029-01-01
Common Stock
300000
300000
D
Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. Option vests over a three year period, with 1/3 of Option vesting on January 1, 2020, and the balance vesting in equal quarterly installments thereafter.
/s/Evan D. Kearns, as Attorney-in-Fact for Jennifer Buell
2019-06-21